CombiGene´s lead project CG01 has received funding from the European Union´s Horizon 2020 research and innovation programme

Business concept and vision

CombiGene’s business concept is to develop effective gene therapies for treatment of difficult-to-treat diseases for which adequate treatment methods are currently lacking. The company intends to take its candidate drugs through the phases of preclinical development and initial clinical studies and, subsequently, either under its own management or in collaboration with other partners, continue development and commercialization.

CombiGene’s head office is in Medicon Village in Lund, Sweden, and the CG01 project is based on the results of research conducted at Lund University and the University of Copenhagen.

CombiGene’s vision is to develop a treatment method that can improve the quality of life for millions of people worldwide.